Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 12, 2023

Lazertinib vs Gefitinib as First-Line Treatment for EGFR-Mutated Advanced NSCLC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Lazertinib Versus Gefitinib as First-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer (NSCLC): Results From LASER301
J. Clin. Oncol 2023 Jun 28;[EPub Ahead of Print], BC Cho, MJ Ahn, JH Kang, RA Soo, T Reungwetwattana, J Chih-Hsin Yang, I Cicin, DW Kim, YL Wu, S Lu, KH Lee, YK Pang, A Zimina, CH Fong, E Poddubskaya, A Sezer, SH How, P Danchaivijitr, Y Kim, Y Lim, T An, H Lee, HM Byun, B Zaric

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading